GT Biopharma, Inc. (GTBP)
Nasdaq: GTBP · Pharmaceutical Preparations · San Francisco, CA · filing with the SEC since 1995
Who owns GT Biopharma, Inc.
As filed with the SECHolders of 5% or more
3
RainForest Partners, LLC holds 9.99% of COMMON STOCK, $0.001 PAR VALUE PER SHARE, as its SCHEDULE 13G filed Sep 15, 2026 says.
Directors and officers
5
report now, of 16 people on the record since 2010. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
RainForest Partners, LLC
SCHEDULE 13G · filed Sep 15, 2026 · COMMON STOCK, $0.001 PAR VALUE PER SHARE
Five Narrow Lane LP
SCHEDULE 13G · filed May 14, 2025 · COMMON STOCK, $0.001 PAR VALUE PER SHARE
Cytovance Biologics Inc
SCHEDULE 13G/A · filed Oct 17, 2024 · Common Stock, par value $0.001
Bristol Capital, LLC
SCHEDULE 13G/A · filed Jun 2, 2025 · Common Stock · reported falling below 5%
What GTBP reports owning in othersstakes of 5% or more, and other ties
GT Biopharma, Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2023 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.